1523-4681/asset/olbannerleft.gif?v=1&s=d7e4c0e37904a489128d3a4e58ba94214db307a9)
1523-4681/asset/olbannerright.gif?v=1&s=854ee0e4d351ead9faaca8bfab3e50b1c7c9d03d)
Perspective
You have free access to this content
Osteosarcoma
Article first published online: 4 MAR 2010
DOI: 10.1002/jbmr.77
Copyright © 2010 American Society for Bone and Mineral Research
Additional Information
How to Cite
Gorlick, R. and Khanna, C. (2010), Osteosarcoma. J Bone Miner Res, 25: 683–691. doi: 10.1002/jbmr.77
Publication History
- Issue published online: 9 APR 2010
- Article first published online: 4 MAR 2010
- Accepted manuscript online: 4 MAR 2010 12:00AM EST
- Manuscript Accepted: 25 FEB 2010
- Manuscript Revised: 31 JAN 2010
- Manuscript Received: 16 NOV 2009
References
- 1, , . Osteosarcoma. In: OrkinS, FisherD, LookA, LuxS, GinsburgD, NathanD, eds. Oncology of Infancy and Childhood. Philadelphia: Saunders Elsevier; 2009: 871–910.
- 2, , , . Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004; 9: 422–441.
- 3, , , et al. Bone tumors. In: KufeD, PollockR, WeichselbaumR, et al., eds. Cancer Medicine, 6th ed., Vol. 2. Hamilton, Ontario, Canada: BC Decker; 2003: 2383–2406.
- 4, , . Pediatric osteosarcoma In: CarrollW, FinlayJ, eds. Cancer in Children and Adolecents. Sudbury, MA: Jones and Bartlett; 2010: 383–394.
- 5
- 6, . Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther. 2009; 9: 511–523.
- 7, , , et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res. 2003; 9: 5442–5453.
- 8, , , , , . Targeted suppression of beta-catenin blocks intestinal adenoma formation in APC Min mice. J Gastrointest Surg. 2008; 12: 1452–1458.
- 9, , . Colon cancer incidence: recent trends in the United States. Cancer Causes Control. 1991; 2: 419–425.
- 10, , . International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009; 125: 229–234.Direct Link:
- 11, , . Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009; 115: 1531–1543.Direct Link:
- 12, , , et al. A crucial role of caspase-3 in osteogenic differentiation of bone marrow stromal stem cells. J Clin Invest. 2004; 114: 1704–1713.
- 13, , , et al. A comparison of intramedullary and juxtacortical low-grade osteogenic sarcoma. Clin Orthop Relat Res. 2008; 466: 1318–1322.
- 14, , , et al. Pediatric surface osteosarcoma: clinical, pathologic, and radiologic features. Pediatr Blood Cancer. 2006; 47: 152–162.Direct Link:
- 15, , , et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 2008; 22: 1662–1676.
- 16, , , et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci U S A. 2008; 105: 11851–11856.
- 17, , , et al. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis. 2009; 30: 1789–1795.
- 18, , , et al. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol. 2009; 219: 294–305.Direct Link:
- 19, , , et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells. 2007; 25: 371–379.Direct Link:
- 20, , , et al. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br J Cancer. 2009; 101: 2064.
- 21, , , et al. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol. 2009; 220: 24–33.Direct Link:
- 22, , , et al. A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br J Cancer. 2007; 97: 1552–1559.
- 23. Wnts, bone and cancer. J Pathol. 2010; 220: 1–4.Direct Link:
- 24, , , et al. Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr Blood Cancer. 2008; 51: 349–355.Direct Link:
- 25, , , et al. Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res. 2007; 25: 964–971.Direct Link:
- 26, , , et al. Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/beta-catenin antagonists against human osteosarcoma cells. Invest New Drugs. 2009.
- 27, , , , . Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model. Clin Orthop Relat Res. 2008; 466: 2039–2045.
- 28, , , et al. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene. 2009; 28: 3197–208.
- 29, , , et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest. 2009; 119: 837–851.
- 30, . Notch and the skeleton. Mol Cell Biol. 2010; 30: 886–896.
- 31, , , et al. Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet. 2009; 18: 1464–1470.
- 32, , , . Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res. 2008; 14: 2962–2969.
- 33, , . Cancer micrometastases. Nat Rev Clin Oncol. 2009; 6: 339–351.
- 34, , , , . Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res. 2005; 11: 4666–4673.
- 35, , . Dormant tumors awaken by a short-term angiogenic burst: the spike hypothesis. Cell Cycle. 2006; 5: 1751–1755.
- 36, . Revisiting the seed and soil in cancer metastasis. Int J Biochem Cell Biol. 2009; 41: 1452–1462.
- 37, , . Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009; 9: 274–284.
- 38. Novel targets with potential therapeutic applications in osteosarcoma. Curr Oncol Rep. 2008; 10: 350–358.
- 39, . Markers of angiogenesis and clinical features in patients with sarcoma. Cancer. 2007; 109: 813–819.Direct Link:
- 40, . Anti-angiogenic therapy for osteosarcoma. Cancer Metastasis Rev. 2006; 25: 707–713.
- 41, , , et al. VEGF blockade decelerates the growth of a murine experimental osteosarcoma. Int J Oncol. 2008; 33: 253–259.
- 42, , , et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004; 10: 182–186.
- 43, , , et al. The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC. Oncogene. 2009; 28: 792–802.
- 44, , , . Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 2005; 65: 2406–2411.
- 45, , , et al. Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin. Oncogene. 2009; 28: 3401–3411.
- 46, , . Integrin trafficking and its role in cancer metastasis. Cancer Metastasis Rev. 2007; 26: 567–578.
- 47, , , et al. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res. 2005; 11: 2561–2567.
- 48, , , et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis. 2008; 25: 201–211.
- 49, , , et al. Chemokine receptor CXCR4-beta1 integrin axis mediates tumorigenesis of osteosarcoma HOS cells. Biochem Cell Biol. 2005; 83: 36–48.
- 50, , , . Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res. 1994; 54: 2803–2807.
- 51, , , , . Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst. 1992; 84: 966–971.
- 52, , , et al. Preclinical in vivo study of new insulin-like growth factor-I receptor–specific inhibitor in Ewing's sarcoma. Clin Cancer Res. 2007; 13: 1322–1330.
- 53, , , . The role of IGF-1R in pediatric malignancies. Oncologist. 2009; 14: 83–91.
- 54, , , et al. Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene. 2008; 27: 684–693.
- 55, , , . Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4: 915–925.
- 56, , , et al. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene. 1995; 10: 739–749.
- 57, , , et al. Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am J Pathol. 1996; 149: 1209–1219.
- 58, , , et al. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J. 2003; 17: 1162–1164.
- 59, , , et al. c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis. 2003; 20: 421–430.
- 60. Targeting PI3K signalling in cancer: opportunities. challenges and limitations Nat Rev Cancer. 2009; 9: 550–562.
- 61, . Translation initiation: a critical signalling node in cancer. Expert Opin Ther Targets. 2009; 13: 1279–1293.
- 62, , , . The mTOR signaling network: insights from its role during embryonic development. Curr Med Chem. 2008; 15: 1192–1208.
- 63, , , , . CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia. 2006; 8: 394–401.
- 64, , , et al. Targeting sarcomas: novel biological agents and future perspectives. Curr Drug Targets. 2009; 10: 937–949.
- 65, , , et al. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res. 2002; 8: 3646–3657.
- 66, , , et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 2005; 65: 1748–1754.
- 67, , , et al. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res. 2005; 65: 8142–8150.
- 68, , , et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008; 455: 1069–1075.
- 69, , , et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2007; 49: 928–940.Direct Link:
- 70, , , et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res. 2008; 14: 4572–4583.
- 71, , , et al. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res. 2007; 67: 32–40.
- 72, . Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer. 2008; 8: 147–156.
- 73, , , et al. Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One. 2009; 4: e4972.
- 74, , , , . Biology of breast cancer bone metastasis. Cancer Biol Ther. 2008; 7: 3–9.
- 75, , , et al. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res. 2008; 14: 6387–6395.
- 76
- 77, , , . Agents Targeting Prostate Cancer Bone Metastasis. Anticancer Agents Med Chem. 2009;
- 78, . Molecular mechanisms of bone metastasis and therapeutic implications. Clin Orthop Relat Res. 2003; (415 Suppl): S100–S104.
- 79, . Drug insight: the use of bisphosphonates for the prevention and treatment of osteoporosis in men. Nat Clin Pract Urol. 2007; 4: 310–320.
- 80. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev. 2008; 34 (Suppl 1): S19–S24.
- 81, , , et al. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am J Hematol. 2009;Direct Link:
- 82, . Role of denosumab in breast cancer. Expert Opin Biol Ther. 2009; 9: 1225–1233.
- 83